226 related articles for article (PubMed ID: 33220015)
1. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
[TBL] [Abstract][Full Text] [Related]
2. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.
Valente S; Tardugno M; Conte M; Cirilli R; Perrone A; Ragno R; Simeoni S; Tramontano A; Massa S; Nebbioso A; Miceli M; Franci G; Brosch G; Altucci L; Mai A
ChemMedChem; 2011 Apr; 6(4):698-712. PubMed ID: 21374822
[TBL] [Abstract][Full Text] [Related]
3. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
4. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
Mehndiratta S; Lin MH; Wu YW; Chen CH; Wu TY; Chuang KH; Chao MW; Chen YY; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Jan; 185():111725. PubMed ID: 31655430
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
6. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
8. Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.
Di Bello E; Sian V; Bontempi G; Zwergel C; Fioravanti R; Noce B; Castiello C; Tomassi S; Corinti D; Passeri D; Pellicciari R; Mercurio C; Varasi M; Altucci L; Tripodi M; Strippoli R; Nebbioso A; Valente S; Mai A
Eur J Med Chem; 2023 Feb; 247():115022. PubMed ID: 36549114
[TBL] [Abstract][Full Text] [Related]
9. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.
Bouchain G; Delorme D
Curr Med Chem; 2003 Nov; 10(22):2359-72. PubMed ID: 14529479
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
13. Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms.
Mehndiratta S; Chen MC; Chao YH; Lee CH; Liou JP; Lai MJ; Lee HY
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):74-84. PubMed ID: 33161799
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
16. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
17. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y
Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941
[TBL] [Abstract][Full Text] [Related]
18. Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.
Zheng H; Dai Q; Yuan Z; Fan T; Zhang C; Liu Z; Chu B; Sun Q; Chen Y; Jiang Y
Bioorg Med Chem; 2022 Jan; 53():116524. PubMed ID: 34847495
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
